BRIEF—Former Valeant exec to take the reins at enGene

enGene, a biotech focused on gene therapies outside the standard viral vector model, has announced that Jason Hanson is taking on the top job at the privately-held Canadian firm.

Mr Hanson has recently served as president and chief executive of Ohana Biosciences, and has previously served as executive vice president at Valeant Pharmaceuticals, as well as corporate vice president at GE Healthcare.

In a statement he said: "I am thrilled to lead enGene into its new phase of growth. The company has made groundbreaking advancements to its gene delivery platform that will transform the way we treat many diseases.  Our vision is to make protein therapies universally available and curative for the improvement of patient's lives."

Anthony Cheung, whom Hanson is to replace as president and chief executive, said: "We are fortunate to have recruited someone with Jason's experience and talent and I really look forward to working with Jason as enGene enters this exciting new stage of development."